^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | chlorpromazine (DRD2 antagonist, DRD3 antagonist, DRD4 antagonist, Serotonin 1A-2A-2B-2C receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial
Published date:
07/19/2023
Excerpt:
...we embarked on a Phase II clinical trial in which CPZ has been added to the standard disease treatment....The RACTAC schedule showed an overall clinical benefit in GBM patients carrying hypo-/un-methylated MGMT gene promoter. When compared with historical cohorts, these patients displayed longer PFS...
DOI:
https://doi.org/10.1101/2023.02.21.23286088
